-

Variantyx Secures $36M Investment As Testing Demand And Market Share Continues To Increase

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Variantyx, a leader in molecular diagnostics, announced today that it has secured an additional $36 million in funding from its portfolio of investors which includes Peregrine Ventures, Pitango HealthTech, New Era Capital Partners and Bosch Ventures. The company, a technology-driven provider of advanced genomic testing for genetic disorders, reproductive health and precision oncology markets has seen a rapid increase in test volumes in the first quarter of 2024, further expanding its market share. The additional investment, which brings the total amount invested in Variantyx to over $125 million, will fund additional technological and commercial expansion, enabling the company to capitalize on the shifting market, seizing the opportunity to provide cutting-edge, genome-based care to a larger number of patients while maintaining strong unit economics and building significant value.

“It’s clear that the current shift away from panel and exome-based testing to whole genome testing benefits patients, providers and payers alike,” said Christine Stanley, Variantyx’s Chief Director of Clinical Genomics. “As a pioneer in clinically-accredited, genome-based testing with tens of thousands of genomes sequenced to date, Variantyx is well-positioned to maintain its leadership in genomic diagnostics with on-going innovation of new genome analysis technologies, providing real improvements in patient outcomes to an increasingly larger subset of the population.”

“The funding demonstrates continued trust and confidence in our ability to deliver on the long-term goals of the company,” said Haim Neerman, CEO of Variantyx. “The additional commercial expansion enabled by this newest investment will help further accelerate our growth to meet the market demand.”

About Variantyx

Variantyx is an award-winning, technology-driven molecular diagnostics company providing disruptive solutions for the genetic disorders, reproductive health, and precision oncology markets. The proprietary whole genome analysis platforms developed by Variantyx allow clinicians to better understand a person’s genetic makeup, leading to unmatched diagnostic capabilities and improved personalized treatment recommendations. For more information, please visit www.variantyx.com.

Contacts

Haim Neerman
Haim.neerman@variantyx.com
(617) 209-2090

Variantyx


Release Versions

Contacts

Haim Neerman
Haim.neerman@variantyx.com
(617) 209-2090

More News From Variantyx

Variantyx Brings the First Combined Short- and Long-Read Whole Genome Sequencing Test to Market with Genomic Unity® 2.0

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Variantyx, a leading molecular diagnostics lab, today announced the launch of Genomic Unity® 2.0, a novel whole genome-based diagnostic test. This advanced test integrates traditional short-read genome sequencing with third-generation long-read genome sequencing, detecting genetic variants that are missed by other methodologies and improving diagnostic yield. Christine Stanley, PhD, FACMG, Chief Genomics & Compliance Officer at Variantyx, commented, “Geno...

Expanded STR Detection Capability Enables Variantyx to Diagnose Additional Genetic Disorders

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Variantyx, a leader in genomic precision medicine, today announced that the set of short tandem repeat (STR) expansions detected by its Genomic Unity® line of whole genome-based tests has been expanded. With these additions, Variantyx becomes one of the first laboratories to offer testing for two recently characterized ataxia variants: the biallelic AAGGG expansion in RFC1 that causes cerebellar ataxia, neuropathy, vestibular areflexia syndrome (CANVAS) and t...

Variantyx Expands Its Reproductive Health Offerings with Launch of a Direct Replacement for Chromosomal Microarray Analysis

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Variantyx, a leader in genomic precision medicine, today announced the launch of its IriSight™ CNV Analysis - a whole genome-based test for the detection of chromosomal abnormalities that correlate with clinical symptoms manifested in a fetus or a pregnancy, that may result in a genetic disorder or pregnancy loss. “IriSight™ CNV Analysis provides the first true alternative to CMA,” said Dr. Allan J. Fisher, FACOG, FACMG, Variantyx Medical Director. “Because t...
Back to Newsroom